Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
05/04/2022 - 08:30 AM
LEXINGTON, Mass. --(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. Kelly Mizer , Aldeyra’s Vice President, Commercial Strategy and Operations, will present at the MOD Live! 2022 meeting, which will take place in Nashville, Tennessee , May 5–7, 2022.
MOD Live! 2022 is an interactive educational program that brings together optometrists and other eye care professionals to discuss new therapies and technologies as well as best practices for patient care. Aldeyra is among several companies selected to participate in the Therapeutics Pipeline session entitled, “The Future of Optometry – Pipeline Game Changers,” which focuses on therapies and technologies in development that may have the potential to change the way optometrists manage ocular diseases. The session will run from 4:30–5:45 pm CT on Thursday, May 5 .
Mr. Mizer will provide a dry eye disease program update on reproxalap, Aldeyra’s investigational new drug currently in Phase 3 clinical trials for the treatment of dry eye disease and allergic conjunctivitis.
About Aldeyra
Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8% ), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. https://www.aldeyra.com/ and follow us on LinkedIn , Facebook , and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006387/en/
Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
ALDX@investorrelations.com
Source: Aldeyra Therapeutics, Inc.
ALDX Rankings
#5198 Ranked by Stock Gains
ALDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALDX
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
